Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28816268 | 0.82 | ALPL (0.50) | ALPLGAAKDM4EACKR3HDAC1 | |
| SCHEMBL14634348 | 0.80 | GAA (0.68) | GAAKDM4EHDAC1POLBKMT2A | |
| SCHEMBL2566003 | 0.78 | HTT (0.56) | ALPLGAAACKR3HDAC1HDAC6 | |
| SCHEMBL29775781 | 0.78 | HTT (0.56) | ALPLGAAACKR3HDAC1HDAC6 | |
| SCHEMBL24800050 | 0.76 | HDAC1 (0.46) | ACKR3HDAC1HDAC6HDAC4DPP4 | |
| SCHEMBL2563085 | 0.71 | GAA (0.68) | GAAKDM4EPOLB | |
| SCHEMBL20405809 | 0.70 | S1PR1 (0.39) | GAAACKR3HDAC1HDAC6HDAC4 | |
| SCHEMBL14363635 | 0.70 | L3MBTL1 (0.47) | GAAKDM4EHDAC1HDAC6HDAC4 | |
| SCHEMBL28869611 | 0.70 | S1PR1 (0.53) | HDAC1HDAC6HDAC4DPP4DPP7 | |
| SCHEMBL28869649 | 0.70 | S1PR1 (0.53) | HDAC1HDAC6HDAC4DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200125564-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2020-04-23 | — | — | US | disclosed |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2020-01-28 | — | — | US | disclosed |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-09-04 | — | — | US | disclosed |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2018-07-12 | — | — | US | disclosed |
| US-9926325-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-03-27 | — | — | US | disclosed |
| EP-3176171-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2552920-B1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20150315199-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2015-11-05 | — | — | US | disclosed |
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8871761-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | EUROSCREEN S.A. (BE) | 2014-10-28 | — | — | US | disclosed |
| EP-2552920-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | Euroscreen S.A. (BE) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| WO-2011121137-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | ALPL 4475/4885GAA 1377/4885KDM4E 3546/4885 |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | ALPL 3996/4885GAA 1199/4885KDM4E 3829/4885 |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | ALPL 4475/4885GAA 1377/4885KDM4E 3546/4885 |
| US-20150315199-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | ALPL 4475/4885GAA 1377/4885KDM4E 3546/4885 |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | ALPL 4475/4885GAA 1377/4885KDM4E 3546/4885 |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | ALPL 3996/4885GAA 1199/4885KDM4E 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.